China's drug regulator accepts NCX 470 NDA for review, advancing Nicox's nitric oxide-donating glaucoma drop toward potential approval in...

FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and...

Headlands Research opens Grand Rapids site led by rheumatology investigator Eric Slavin, expanding clinical trial capacity in the Midwest.

Velocity Clinical and Stitch expand partnership across 70+ sites, achieving a 9-point reduction in no-show rates and boosting screening...

Phase 3 study shows aQIVc demonstrated superior immunogenicity against influenza strains in adults 50 and older, with responses sustained...

FDA clears Prelude's PRT13722 Phase 1 trial in HR-positive breast cancer, advancing the oral KAT6A degrader toward patient enrollment.

The problem isn't that fewer women get aortic stenosis. It's that the entire pipeline, from diagnosis to device, was...

The FDA approval of etripamil for PSVT occurred in December, 2025. Investigation about a potential role of etripamil in...

TruTechnologies co-founder Rick Graham argues that the industry's real execution problem is not a modeling problem.

Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate...